drugset / Trial / NCT04102618
A Window-of-opportunity Study of Pelareorep in Early Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out if pelareorep in combination with different therapies helps to reduce the growth of breast cancer cells and increase the immune system's response to cancer. This study will also help to understand what this treatment does to the tumor. In addition, the safety of the combination treatments with pelareorep will be evaluated.
Timeline
- Start
- 2019-03-29
- Primary completion
- 2022-04-20
- Completion
- 2022-04-20
Outcome
Outcome not reported
Stopped (Enrollment): “Enrollment into AWARE cohorts1-4 have concluded and the primary objective and core goals for the study were met.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Letrozole | Other / unclassified | 2.5 mg | Oral |
| Subject | REOLYSIN® | Other / unclassified | 4.5e+10 unknown | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | 8 mg/kg | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | 600 mg | Intravenous |